Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.50 8.75% 43.50 43.00 44.00 43.50 39.00 40.00 842,220 14:37:37
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -9.6 -8.1 - 55

C4X Discovery Holdings PLC Grant of options and Directors Dealing

14/12/2020 5:14pm

UK Regulatory (RNS & others)


C4x Discovery (LSE:C4XD)
Historical Stock Chart


From Oct 2020 to Apr 2021

Click Here for more C4x Discovery Charts.

TIDMC4XD

RNS Number : 6161I

C4X Discovery Holdings PLC

14 December 2020

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Grant of options and Directors Dealing

14 December 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that a total of 600,000 options over ordinary shares of the Company were awarded pursuant to the EMI 2014 Plan to certain employees, which includes 200,000 options each to Dr Clive Dix, Chief Executive Officer, Dr Craig Fox, Chief Scientific Officer and Brad Hoy, Chief Financial Officer, as set out below.

 
 Director    Position            Number of share    Option exercise    Total number 
                                  options awarded    price per share    of options 
                                                     (pence)            held 
 Dr Clive    Chief Executive 
  Dix         Officer            200,000            20                 645,000 
            ------------------  -----------------  -----------------  ------------- 
 Dr Craig    Chief Scientific 
  Fox         officer            200,000            20                 700,000 
            ------------------  -----------------  -----------------  ------------- 
             Chief Financial 
 Brad Hoy     Officer            200,000            20                 800,000 
            ------------------  -----------------  -----------------  ------------- 
 

The options have an exercise price of 20 pence, being the average 5-day VWAP of the ordinary shares to the 11 December 2020. The options can be exercised at any time between three and 10 years of them being granted.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging managerial responsibilities/person closely associated 
 a)    Name(s)                                                  Dr Clive Dix 
      -------------------------------------------------------  ------------------------------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------------------------------------------------------- 
                                                                Chief Executive Officer, Director 
  a)    Position/status 
      -------------------------------------------------------  ------------------------------------------------------- 
 b)    Initial notification/Amendment                           Initial Notification 
      -------------------------------------------------------  ------------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, auction platform, auctioneer 
        or auction monitor 
      ---------------------------------------------------------------------------------------------------------------- 
 a)    Name                                                     C4X Discovery Holdings plc 
      -------------------------------------------------------  ------------------------------------------------------- 
 b)    LEI                                                      213800UHNL82E323O870 
      -------------------------------------------------------  ------------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
        each type of transaction; (iii) each date; and (iv) each place where transactions have been 
        conducted 
      ---------------------------------------------------------------------------------------------------------------- 
 a)    Description of the financial instrument, type of         Options over ordinary shares of one penny (GBP0.01) 
       instrument                                               each in the share capital of the Company 
                                                                - EMI 2014 Plan 
       Identification code 
 
                                                                ISIN GB00BQQ2RV18 
      -------------------------------------------------------  ------------------------------------------------------- 
 b)    Nature of the transaction                                Grant of o ptions over o rdinary s hares 
      -------------------------------------------------------  ------------------------------------------------------- 
 c)    Price(s) and volume(s)                                    Price(s)   Volume(s) 
                                                                  20 p       20 0,000 
      -------------------------------------------------------  ------------------------------------------------------- 
 d)    Aggregated information 
      -------------------------------------------------------  ------------------------------------------------------- 
 e)    Date of the transaction                                  14 December 2020 
      -------------------------------------------------------  ------------------------------------------------------- 
 f)    Place of the transaction                                 London Stock Exchange - AIM 
      -------------------------------------------------------  ------------------------------------------------------- 
 
 
 1     Details of the person discharging managerial responsibilities/person closely associated 
 a)    Name                                                     Dr Craig Fox 
      -------------------------------------------------------  ------------------------------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------------------------------------------------------- 
                                                                Chief Scientific Officer, Director 
  a)    Position/status 
      -------------------------------------------------------  ------------------------------------------------------- 
 b)    Initial notification/Amendment                           Initial Notification 
      -------------------------------------------------------  ------------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, auction platform, auctioneer 
        or auction monitor 
      ---------------------------------------------------------------------------------------------------------------- 
 a)    Name                                                     C4X Discovery Holdings plc 
      -------------------------------------------------------  ------------------------------------------------------- 
 b)    LEI                                                      213800UHNL82E323O870 
      -------------------------------------------------------  ------------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
        each type of transaction; (iii) each date; and (iv) each place where transactions have been 
        conducted 
      ---------------------------------------------------------------------------------------------------------------- 
 a)    Description of the financial instrument, type of         Options over ordinary shares of one penny (GBP0.01) 
       instrument                                               each in the share capital of the Company 
                                                                - EMI 2014 Plan 
       Identification code 
 
                                                                ISIN GB00BQQ2RV18 
      -------------------------------------------------------  ------------------------------------------------------- 
 b)    Nature of the transaction                                Grant of o ptions over o rdinary s hares 
      -------------------------------------------------------  ------------------------------------------------------- 
 c)    Price(s) and volume(s)                                    Price(s)   Volume(s) 
                                                                  20 p       20 0,000 
      -------------------------------------------------------  ------------------------------------------------------- 
 d)    Aggregated information 
      -------------------------------------------------------  ------------------------------------------------------- 
 e)    Date of the transaction                                  14 December 2020 
      -------------------------------------------------------  ------------------------------------------------------- 
 f)    Place of the transaction                                 London Stock Exchange - AIM 
      -------------------------------------------------------  ------------------------------------------------------- 
 
 
 1     Details of the person discharging managerial responsibilities/person closely associated 
 a)    Name                                                     Brad Hoy 
      -------------------------------------------------------  ------------------------------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------------------------------------------------------- 
                                                                Chief Financial Officer, Director 
  a)    Position/status 
      -------------------------------------------------------  ------------------------------------------------------- 
 b)    Initial notification/Amendment                           Initial Notification 
      -------------------------------------------------------  ------------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, auction platform, auctioneer 
        or auction monitor 
      ---------------------------------------------------------------------------------------------------------------- 
 a)    Name                                                     C4X Discovery Holdings plc 
      -------------------------------------------------------  ------------------------------------------------------- 
 b)    LEI                                                      213800UHNL82E323O870 
      -------------------------------------------------------  ------------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
        each type of transaction; (iii) each date; and (iv) each place where transactions have been 
        conducted 
      ---------------------------------------------------------------------------------------------------------------- 
 a)    Description of the financial instrument, type of         Options over ordinary shares of one penny (GBP0.01) 
       instrument                                               each in the share capital of the Company 
                                                                - EMI 2014 Plan 
       Identification code 
 
                                                                ISIN GB00BQQ2RV18 
      -------------------------------------------------------  ------------------------------------------------------- 
 b)    Nature of the transaction                                Grant of o ptions over o rdinary s hares 
      -------------------------------------------------------  ------------------------------------------------------- 
 c)    Price(s) and volume(s)                                    Price(s)   Volume(s) 
                                                                  20 p       20 0,000 
      -------------------------------------------------------  ------------------------------------------------------- 
 d)    Aggregated information 
      -------------------------------------------------------  ------------------------------------------------------- 
 e)    Date of the transaction                                  14 December 2020 
      -------------------------------------------------------  ------------------------------------------------------- 
 f)    Place of the transaction                                 London Stock Exchange - AIM 
      -------------------------------------------------------  ------------------------------------------------------- 
 

- Ends -

Contacts

 
 C4X Discovery Holdings 
 Mo Noonan, Communications                    +44 (0)787 6444977 
 
 Panmure Gordon (UK) Limited (NOMAD and 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate 
  Finance)                                    +44 (0)20 7886 2500 
 Rupert Dearden (Corporate Broking) 
 
 C4X Discovery Media - Consilium Strategic 
  Communications 
 Mary-Jane Elliott, Chris Gardner, Matthew 
  Neal                                        +44 (0)203 709 5700 
 

Notes to Editors:

About C4X Discovery

C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m, which is now in a Phase I clinical study.

C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

For additional information please go to: www.c4xdiscovery.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUSABRROUUAAA

(END) Dow Jones Newswires

December 14, 2020 12:14 ET (17:14 GMT)

1 Year C4x Discovery Chart

1 Year C4x Discovery Chart

1 Month C4x Discovery Chart

1 Month C4x Discovery Chart
ADVFN Advertorial
Your Recent History
LSE
C4XD
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210420 14:18:47